Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Delivers Bioinformatics Platform to Plough

Premium

WALTHAM, Mass.--Genome Therapeutics here has delivered a customized bioinformatics platform to Schering-Plough as part of a research alliance between the two companies aimed at discovering antiinfective agents that are effective against drug-resistant bacteria. The delivery triggered a milestone payment to Genome Therapeutics of an undisclosed sum.

Two years ago, the firms entered into a multiyear alliance worth $43.5 million. The payment for delivering the bioinformatics platform was the drug company's fifth milestone installment. Previous payments, totaling about $11 million, were for such events as delivering a sequence for the Staphylococcus aureus bacteria and providing multiple assays for validated targets. The delivery of PathoGenome, Genome Therapeu tics' microbial and fungal sequence database, to Schering-Plough, is the first bioinformatics transfer between the two firms, a Genome Therapeutics spokesman said.

PathoGenome was released in May and is also used by Bayer AG and Bristol-Myers Squibb. The proprietary bioinformatics platform combines detailed genetic and biological information in a way that lets researchers analyze and compare genomic information to identify potential drug targets.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.